MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma

BACKGROUND: Malignant peritoneal mesothelioma (MPM) is a rare tumoral disease characterized by the diffuse involvement of the peritoneal serosa. The standard frontline treatment of MPM is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) unless the peritoneal disease is co...

Descripción completa

Detalles Bibliográficos
Autores principales: Sgarbura, Olivia, Gourgou, Sophie, Tosi, Diego, Bakrin, Naoual, Bouazza, Nabila, Delaine, Stéphanie, De Forges, Hélène, Pocard, Marc, Quénet, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693480/
https://www.ncbi.nlm.nih.gov/pubmed/31417958
http://dx.doi.org/10.1515/pp-2019-0010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693480/
https://www.ncbi.nlm.nih.gov/pubmed/31417958
http://dx.doi.org/10.1515/pp-2019-0010

Ejemplares similares